Beijing Wantai Biological Pharmacy Enterprise Co (603392) Fair Value & Analysis
Healthcare · CN · Market cap 35.9B CNY
Analysis
Beijing Wantai Biological Pharmacy Enterprise Co (603392) currently trades at ¥28.64, while our model-based Fair Value estimate is ¥42.23 — implying the stock looks roughly 47.5% undervalued today. We read business quality at 93/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
About the company
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. research, develops, produces, and sells biological diagnostic tests and vaccines in China and internationally. The company offers in vitro diagnostics and automated laboratory instruments, including Wan600, Wan BC2800, WanTLA immunoassay and biochemistry analyzers; chemiluminescence and biochemistry tests, including novel diagnostic tests for detection of Hepatitis virus infections; P-85 Ab for nasopharyngeal cancer screening; and TB-IGRA for large population screening. It also provides diagnostic assays, such as high-value Hepatitis B core antibody tests, Hepatitis E Urine tests, Hepatitis D virus detection, IL-6, HIV 4th generation CLIA, Helicobacter pylori antibody, gastrin-17, and soluble transferrin receptor assays; and enzyme-linked immunosorbent assay (ELISA), colloidal gold, molecular, clinical laboratory quality control products, and bioactive materials for various infectious diseases, such as HIV, Hepatitis, Tuberculo…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.